Quantcast
Last updated on April 16, 2014 at 12:34 EDT

Latest Nycomed Stories

2014-03-18 04:21:58

ZURICH, March 18, 2014 /PRNewswire/ -- Takeda Pharmaceuticals International GmbH ("Takeda") today announced that Giles Platford has been appointed Head of Commercial Operations, Emerging Markets, reporting to Christophe Weber, Chief Operating Officer of Takeda Pharmaceutical Company Limited as of April 1, 2014. In this role he will be responsible for leading the continued expansion of Takeda's commercial activities in this region, which comprises Russia-CIS, Latin...

2014-03-06 16:27:44

SAN DIEGO and MORRIS PLAINS, N.J., March 6, 2014 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Immunomedics, Inc. (NASDAQ: IMMU) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of New Jersey. The complaint alleges that the company and certain of its officers and directors violated the Securities and Exchange Act of 1934 between May 9, 2013 and October 9, 2013 (the "Class Period")....

2013-08-22 08:27:40

ZURICH, August 22, 2013 /PRNewswire/ -- Demonstrates Takeda's long-term commitment to the Latin American market Takeda Pharmaceuticals International GmbH ("Takeda") today announced further expansion of its presence in Latin America with the launch of a wholly-owned subsidiary in Peru. Takeda Peru S.R.L. (Takeda Peru or "the Company") will be headquartered in Lima and will be responsible for the sales and marketing of Takeda's products in Peru. Takeda is building...

2013-03-21 04:20:56

ZURICH, Switzerland, March 21, 2013 /PRNewswire/ -- Demonstrates Takeda's long-term commitment to the Latin American market Takeda Pharmaceuticals International GmbH ("Takeda"), today announced further expansion of its presence in Latin America with the launch of its wholly-owned subsidiary in Ecuador. Takeda Ecuador S.A. (Takeda Ecuador or "the Company") will be headquartered in Quito and will be responsible for the sales and marketing of Takeda's products in Ecuador....

2012-03-14 04:00:00

DUBAI, UAE, March 14, 2012 /PRNewswire/ -- - United Arab Emirates is the First Country in the Middle East to Introduce Omnaris(R) to Region's Allergy Sufferers - Nycomed, a Takeda company, today announced that Omnaris(R) (ciclesonide) Nasal Spray is now available in the United Arab Emirates for the treatment of allergic rhinitis, also known as nasal allergies and hay fever, in adults and adolescents over the age of 12. Omnaris(R) Nasal Spray is a long-lasting...

2012-02-01 08:00:00

ZURICH, Feb. 1, 2012 /PRNewswire/ -- The buzz is growing stronger and stronger for one of the most talked-about events in 2012- the Pharma CI Europe Conference on February 21-22, 2012 at the Renaissance Zurich Hotel in Switzerland (http://pharmaciconference.com/ ). "With more than 150 top pharmaceutical executives already attending, people are already saying that this event is sure to make waves among the industry's influential decision makers," says conference organizer Amy Yueh. "After...

2012-01-30 15:15:00

CUPERTINO, Calif., Jan. 30, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today reported that Takeda (through Nycomed) has given notice that it is returning its development and commercialization rights to POSIDUR(TM) (SABER(TM)-Bupivacaine) in Europe and their other licensed territories. Takeda acquired its rights to POSIDUR through its acquisition of Nycomed in September, 2011. POSIDUR is a post-operative pain relief depot that utilizes DURECT's patented SABER(TM)...

2012-01-18 03:00:00

OSAKA, Japan, January 18, 2012 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) announced today strategic measures to better align its global workforce and consolidate site operations in order to integrate legacy Nycomed operations, strengthen its presence in more than 70 countries, adapt to changing market conditions and maintain a focus on growth through innovation and culture, as outlined in its 2011-2013 Mid-Range Plan (MRP). The measures...

2011-10-06 02:00:00

NEW YORK, Oct. 6, 2011 /PRNewswire/ -- Avista Capital Partners, a leading private equity firm, today announced that it has hired Hakan Bjorklund, the departing Chief Executive Officer of Nycomed, as Healthcare Operating Executive. Mr. Bjorklund worked closely with Avista on the development of Nycomed during Avista's ownership of the company, which was recently sold to Takeda Pharmaceuticals Company Limited for Euro 9.6 billion. Under Mr. Bjorklund's leadership, Nycomed was transformed...

2011-09-30 06:00:00

OSAKA, Japan, September 30, 2011 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) announced it has completed its acquisition of Nycomed A/S ("Nycomed") for 9.6 billion Euro on a cash-free, debt-free basis and made Nycomed a wholly owned subsidiary of Takeda effective the same day. Dr. Frank Morich has been named CEO of Nycomed in addition to his current role as Executive Vice President (EVP), International Operations (Americas/Europe), Takeda...